• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Other 1 o Market segments o Comparison by Other1 o Renal pruritus - Market size and forecast 2019-2024 o Cholestatic pruritus - Market size and forecast 2019-2024 o Hematologic pruritus - Market size and forecast 2019-2024 o Endocrine pruritus - Market size and forecast 2019-2024 o Oncological pruritus - Market size and forecast 2019-2024 o Market opportunity by Other1 • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Market challenges o Market trends • Vendor Landscape o Overview o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Abbott Laboratories o Allergan Plc o Astellas Pharma Inc. o Cipla Inc. o GlaxoSmithKline Plc o Merck & Co. Inc. o Novartis AG o Pfizer Inc. o Sanofi o Sun Pharmaceutical Industries Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 5 • 5.Key Finding 6 • 6.Key Finding 7 • 7.Key Finding 8 • 8.Parent market • 9.Market characteristics • 10.Offerings of vendors included in the market definition • 11.Market segments • 12.Global - Market size and forecast 2019 - 2024 ($ million) • 13.Global market: Year-over-year growth 2019 - 2024 (%) • 14.Five forces analysis 2019 & 2024 • 15.Bargaining power of buyers • 16.Bargaining power of suppliers • 17.Threat of new entrants • 18.Threat of substitutes • 19.Threat of rivalry • 20.Market condition - Five forces 2019 • 21.Other1 - Market share 2019-2024 (%) • 22.Comparison by Other1 • 23.Renal pruritus - Market size and forecast 2019-2024 ($ million) • 24.Renal pruritus - Year-over-year growth 2019-2024 (%) • 25.Cholestatic pruritus - Market size and forecast 2019-2024 ($ million) • 26.Cholestatic pruritus - Year-over-year growth 2019-2024 (%) • 27.Hematologic pruritus - Market size and forecast 2019-2024 ($ million) • 28.Hematologic pruritus - Year-over-year growth 2019-2024 (%) • 29.Endocrine pruritus - Market size and forecast 2019-2024 ($ million) • 30.Endocrine pruritus - Year-over-year growth 2019-2024 (%) • 31.Oncological pruritus - Market size and forecast 2019-2024 ($ million) • 32.Oncological pruritus - Year-over-year growth 2019-2024 (%) • 33. Market opportunity by Other1 • 34.Customer landscape • 35.Market share by geography 2019-2024 (%) • 36.Geographic comparison • 37.North America - Market size and forecast 2019-2024 ($ million) • 38.North America - Year-over-year growth 2019-2024 (%) • 39.Europe - Market size and forecast 2019-2024 ($ million) • 40.Europe - Year-over-year growth 2019-2024 (%) • 41.APAC - Market size and forecast 2019-2024 ($ million) • 42.APAC - Year-over-year growth 2019-2024 (%) • 43.ROW - Market size and forecast 2019-2024 ($ million) • 44.ROW - Year-over-year growth 2019-2024 (%) • 45.Key leading countries • 46.Market opportunity by geography ($ million) • 47.Impact of drivers and challenges • 48.Vendor landscape • 49.Landscape disruption • 50.Industry risks • 51.Vendors covered • 52.Market positioning of vendors • 53.Abbott Laboratories - Overview • 54.Abbott Laboratories - Business segments • 55.Abbott Laboratories - Key offerings • 56.Abbott Laboratories - Key customers • 57.Abbott Laboratories - Segment focus • 58.Allergan Plc - Overview • 59.Allergan Plc - Business segments • 60.Allergan Plc - Key offerings • 61.Allergan Plc - Key customers • 62.Allergan Plc - Segment focus • 63.Astellas Pharma Inc. - Overview • 64.Astellas Pharma Inc. - Business segments • 65.Astellas Pharma Inc. - Key offerings • 66.Astellas Pharma Inc. - Key customers • 67.Astellas Pharma Inc. - Segment focus • 68.Cipla Inc. - Overview • 69.Cipla Inc. - Business segments • 70.Cipla Inc. - Key offerings • 71.Cipla Inc. - Key customers • 72.Cipla Inc. - Segment focus • 73.GlaxoSmithKline Plc - Overview • 74.GlaxoSmithKline Plc - Business segments • 75.GlaxoSmithKline Plc - Key offerings • 76.GlaxoSmithKline Plc - Key customers • 77.GlaxoSmithKline Plc - Segment focus • 78.Merck & Co. Inc. - Overview • 79.Merck & Co. Inc. - Business segments • 80.Merck & Co. Inc. - Key offerings • 81.Merck & Co. Inc. - Key customers • 82.Merck & Co. Inc. - Segment focus • 83.Novartis AG - Overview • 84.Novartis AG - Business segments • 85.Novartis AG - Key offerings • 86.Novartis AG - Key customers • 87.Novartis AG - Segment focus • 88.Pfizer Inc. - Overview • 89.Pfizer Inc. - Business segments • 90.Pfizer Inc. - Key offerings • 91.Pfizer Inc. - Key customers • 92.Pfizer Inc. - Segment focus • 93.Sanofi - Overview • 94.Sanofi - Business segments • 95.Sanofi - Key offerings • 96.Sanofi - Key customers • 97.Sanofi - Segment focus • 98.Sun Pharmaceutical Industries Ltd. - Overview • 99.Sun Pharmaceutical Industries Ltd. - Business segments • 100.Sun Pharmaceutical Industries Ltd. - Key offerings • 101.Sun Pharmaceutical Industries Ltd. - Key customers • 102.Sun Pharmaceutical Industries Ltd. - Segment focus • 103.Currency conversion rates for US$ • 104.Research Methodology • 105.Research Methodology • 106.Validation techniques employed for market sizing • 107.Information sources • 108.List of abbreviations

Abbott Laboratories, Allergan Plc, Astellas Pharma Inc., Cipla Inc., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.